EXTH-06. DOWN-REGULATION OF PD-L1 VIA FKBP5 LOWERED BY A CYCLOOXYGENASE-2 INHIBITOR IN GSCs AND GBM CELLS MAY BE ATTRIBUTABLE TO ENHANCE ANTITUMOR EFFECTS OF IMMUNOTHERAPY

BACKGROUND: Antitumor therapies targeting programmed cell death-1 (PD-1)/its ligand-1 (PD-L1) are influential at present stage. However, in glioblastoma (GBM), the expression of PD-L1 is variable and the role of anti-PD-1 antibody therapy is still unclear. The high expression of PD-L1 affects cell p...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:Neuro Oncol
Auteurs principaux: Yamaguchi, Izumi, Nakajima, Kohei, Shono, Kenji, Mizobuchi, Yoshifumi, Fujihara, Toshitaka, Kitazato, Keiko, Takagi, Yasushi
Format: Artigo
Langue:Inglês
Publié: Oxford University Press 2019
Sujets:
Experimental Therapeutics
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC6847806/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/noz175.340
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires